Home › Biochemistry › Porphyria: Pathophysiology and Mechanisms

Porphyria

For medical students2 min readUpdated 2026-10-10

Porphyrias are a group of disorders caused by genetic defects or dysregulation of enzymes in the heme biosynthesis pathway. The primary clinical issue stems not from the deficiency of the end-product (heme), but from the massive accumulation of toxic upstream metabolic intermediates.

EtiologyInherited defects in heme synthesis genes or regulatory failure.

TriggersDrugs that induce 5-aminolevulinic acid synthase (e.g., sulfonamides).

PhotodermatosisOccurs due to the formation of reactive oxygen species in the skin upon light exposure.

NeurotoxicityLinked to the structural similarity between 5-aminolevulinic acid and GABA.

Classification and Causes

Broadly, the causes of porphyrias are divided into two categories:

Primary Porphyrias: Based on direct hereditary defects. The problem lies within the structure of the genes encoding enzymes of the heme synthesis chain.
Secondary Porphyrias: Develop as a consequence of dysregulation in heme synthesis, frequently triggered by external factors (such as medications).

Mechanism of Drug Induction (Sulfonamides as an Example)

A classic scenario for a porphyria exacerbation is the administration of medications such as sulfonamides. The mechanism of an acute attack is a cascade of biochemical reactions:

Drug Metabolism: Sulfonamides are metabolized in the liver via the cytochrome P450 system, which incorporates heme as a prosthetic group.
Depletion of Heme: Active functioning of cytochrome P450 requires a continuous supply of heme, leading to a sharp drop in its intracellular concentration.
Regulatory Breakdown: Normally, heme acts as an allosteric inhibitor and corepressor of the rate-limiting enzyme, 5-aminolevulinic acid synthase (ALA synthase). When heme levels drop, this repression is lifted (derepression of ALA synthase synthesis).
Accumulation of Intermediates: Increased ALA synthase activity triggers an uncontrolled pathway. Intermediate synthesis products—5-aminolevulinic acid, porphobilinogen, and porphyrinogens—accumulate massively in the blood and tissues.

Pathogenesis of Clinical Symptoms

The accumulation of heme synthesis intermediates explains the entire clinical picture, including the classic red urine (due to the excretion of excess porphyrins).

Photosensitization and Skin Damage (Photodermatosis) Excess porphyrinogens deposit in the skin. Under ultraviolet light, they are converted into porphyrins. These molecules react with oxygen, generating reactive oxygen species (ROS) and free radicals that destroy skin cells.

Neurotoxicity Porphyrinogens exert marked toxicity on the nervous system, causing severe neuropsychiatric symptoms. One of the key mechanisms is the structural similarity of accumulated 5-aminolevulinic acid (ALA) to the primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA).

Mnemonic

Heme is the 'brake' for ALA synthase. Cytochrome consumes heme -> brakes fail -> the factory uncontrollably pumps out toxic porphyrins.

Frequently asked questions

Deficiencies in which specific enzymes cause the various types of primary porphyria?

Different types of primary porphyrias are caused by genetic defects in the following heme biosynthesis enzymes:

ALA dehydratase — ALA dehydratase-deficient porphyria.
Hydroxymethylbilane synthase (including PBG deaminase) — Acute intermittent porphyria.
Uroporphyrinogen III synthase — Congenital erythropoietic porphyria.
Uroporphyrinogen decarboxylase — Porphyria cutanea tarda.
Coporphyrinogen oxidase — Hereditary coproporphyria.
Protoporphyrinogen oxidase — Variegate porphyria.
Ferrochelatase — Erythropoietic protoporphyria.

What other drugs, besides sulfonamides, are classic inducers of porphyria?

In addition to sulfonamides, sources list the following as inducers of 5-aminolevulinic acid synthase:

Barbiturates and their derivatives — definitive porphyrinogenic drugs; their use is contraindicated in acute porphyrias.
Diclofenac.
Estrogens.
Progestins.

What clinical syndromes (e.g., gastrointestinal), besides neuropsychiatric disorders and photodermatosis, are characteristic of an acute porphyria attack?

An acute porphyria attack is characterized by abdominal pain syndrome. Key symptoms include abdominal pain that has an acute onset and reaches maximal intensity within 2–3 days; the character and localization can vary widely. The abdominal pain can mimic an 'acute abdomen': peritoneal signs are absent, and initial laboratory inflammatory markers are normal. The exact pain mechanism remains unclear, with the primary theory being autonomic dysfunction and an alternative theory involving vasospasm or intestinal ischemia.

Why is a porphyria attack often accompanied by skin lesions?

Porphyrinogens accumulate in the skin. Upon exposure to light, they convert into porphyrins, react with oxygen, and form active radicals that destroy cells.

How are 5-aminolevulinic acid and neuropsychiatric disorders linked?

5-aminolevulinic acid (ALA) is structurally very similar to GABA, the main inhibitory neurotransmitter, leading to nervous system dysfunction.

Why do sulfonamide drugs require heme?

The metabolism of sulfonamides heavily engages the cytochrome P450 system. Heme is an essential prosthetic group required for cytochrome function.

Go deeper

Biochemical description of the first two reactions of heme synthesis (in mitochondria and cytosol)
The role of 5-aminolevulinic acid and porphobilinogen as intermediates
Principles of allosteric enzyme regulation using ALA synthase as an example
Structure and functions of the cytochrome P450 system